Max Crispin is Supernumerary Fellow at Oriel and Professor of Glycobiology at the University of Southampton.
Max read Biochemistry at Oriel as an undergraduate and, after doctoral studies at Oxford and The Scripps Research Institute, went on to run the Glycoprotein Therapeutics Laboratory within Oxford’s Department of Biochemistry. At Oriel he has had a variety of roles including as a Tutorial Fellow in Biochemistry, Against Breast Cancer Senior Research Fellow, and Senior Dean. He has also been a Lecturer in Biochemistry at Corpus Christi College. Max moved to the University of Southampton in 2017 to take up a Professorship and was subsequently elected to a Supernumerary Fellowship at Oriel. Max will be supporting the Biochemistry teaching team during Michaelmas and Hilary terms of the 2021-22 academic year while Professor Cox and Dr Bublitz are on leave.
Max’s research continues to be supported by Against Breast Cancer and he works closely with the charity and the current Oriel Against Breast Cancer Fellows.
Max’s laboratory operates at the nexus of glycoprotein engineering and glycan analytics and is currently mainly focussed on the design of antibody therapeutics against breast cancer and in supporting the development of vaccine candidates against HIV. Max co-founded Immago Biosystems Ltd with the late Chris Scanlan, which was subsequently acquired by Hansa Biopharma.
Max’s laboratory is funded by the Bill & Melinda Gates Foundation through the Collaboration for AIDS/Vaccine Discovery, the International AIDS Vaccine Initiative, the US National Institute of Health, the European Union Horizon 2020 programme, and by Against Breast Cancer. He is Professor Adjunct in the Department of Immunology and Microbiology at The Scripps Research Institute, California, USA, and was listed by Web of Science as one of the world’s most highly cited researchers for 2019.
A full list of Max’s publications can be found here.